Cyproterone acetate in the treatment of advanced carcinoma of the prostate

R. B. Smith, P. C. Walsh, W. E. Goodwin

Research output: Contribution to journalArticlepeer-review

Abstract

28 patients with refractory metastatic carcinoma of the prostate were treated with cyproterone acetate (a synthetic progestin) in doses of 300 mg. daily. In 19 patients followup examinations and evaluations demonstrated beneficial results. It is believed that cyproterone acetate has an important place in the hormonal treatment of prostatic cancer.

Original languageEnglish (US)
Pages (from-to)106-108
Number of pages3
JournalJournal of Urology
Volume110
Issue number1
DOIs
StatePublished - Jan 1 1973
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Cyproterone acetate in the treatment of advanced carcinoma of the prostate'. Together they form a unique fingerprint.

Cite this